HSR21-057: Cost-Effectiveness of Cemiplimab vs Pembrolizumab for the First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (aNSCLC) and Programmed Death-Ligand 1 (PD-L1) Expression ≥50% in the US

Authors :: Gerasimos Konidaris
Florence Wilson
Meena Venkatachalam
Patricia Guyot
Chieh-I Chen
Andreas Kuznik
Sam Keeping
Emily Glowienka
Keith Syson Chan
Caitlin Smare
Yingxin Xu
Kokuvi Atsou
Source :: Journal of the National Comprehensive Cancer Network. 19:HSR21-057
Publication Year :: 2021
Publisher :: Harborside Press, LLC, 2021.

Subjects :: business.industry
Cost effectiveness
Pembrolizumab
Ligand (biochemistry)
medicine.disease
First line treatment
Oncology
Cancer research
medicine
Pd l1 expression
Non small cell
Lung cancer
business
Programmed death

Full Text Access

Tools